Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20050045192 A1
Publication typeApplication
Application numberUS 10/943,434
Publication date3 Mar 2005
Filing date16 Sep 2004
Priority date22 Jun 1998
Also published asDE69942833D1, EP1096875A1, EP1096875A4, EP1096875B1, EP2258258A2, EP2258258A3, EP2258258B1, US6270464, US6699205, US6730042, US8292822, US20010049481, US20020058883, US20040204660, US20040210160, US20050033195, US20060079829, WO1999066834A1
Publication number10943434, 943434, US 2005/0045192 A1, US 2005/045192 A1, US 20050045192 A1, US 20050045192A1, US 2005045192 A1, US 2005045192A1, US-A1-20050045192, US-A1-2005045192, US2005/0045192A1, US2005/045192A1, US20050045192 A1, US20050045192A1, US2005045192 A1, US2005045192A1
InventorsRichard Fulton, William Dubrul
Original AssigneeArtemis Medical, Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Biopsy localization method and device
US 20050045192 A1
Abstract
Biopsy localization devices and methods made according to the invention include a bioresorbable body, such as a gelatin, polylactic acid, and/or polyglycolic acid. The bioresorbable body preferably carries a radiopaque marker. The bioresorbable body preferably swells to fill the biopsied open region. The bioresorbable body and radiopaque marker permit the biopsy site to be relocated by various techniques, including mammography and ultrasound.
Images(4)
Previous page
Next page
Claims(24)
1. A target tissue localization device comprising:
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising gelatin; and
a radiopaque marker carried by the bioresorbable body.
2. The target tissue localization device of claim 1, wherein the bioresorbable body is remotely visualizable by at least one of ultrasound and mammography.
3. The target tissue localization device of claim 1, wherein the radiopaque marker is contained within the bioresorbable body.
4. The target tissue localization device of claim 1, wherein the bioresorbable body comprises at least one bioresorbable body.
5. The target tissue localization device of claim 1, wherein the bioresorbable body swells upon contact with body fluid.
6. The target tissue localization device of claim 5, wherein the bioresorbable body swells to substantially fill the biopsy site.
7. A method for marking a biopsy cavity comprising the steps of:
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising gelatin;
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and
testing the biopsy specimen.
8. The method of claim 7, further comprising the step of relocating the biopsy site by detecting the radiopaque marker.
9. The method of claim 7, wherein the bioresorbable body comprises at least one bioresorbable body.
10. The method of claim 7, wherein the radiopaque marker is contained within the bioresorbable body.
11. The method of claim 7, wherein the radiopaque marker is detected by mammography.
12. The method of claim 7, wherein the radiopaque marker is detected by ultrasound.
13. The method of claim 7, wherein the bioresorbable body swells upon contact with body fluid.
14. The method of claim 7, wherein the bioresorbable body swells to substantially fill the biopsy site.
15. A target tissue localization device comprising:
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising polylactic acid; and
a radiopaque marker carried by the bioresorbable body.
16. The target tissue localization device of claim 15, wherein the bioresorbable body further comprises polyglycolic acid.
17-21. (Canceled)
22. A method for marking a biopsy cavity comprising the steps of:
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising polylactic acid;
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and
testing the biopsy specimen.
23. The method of claim 22, wherein the bioresorbable body further comprises polyglycolic acid.
24-30. (Canceled)
31. A target tissue localization device comprising:
an elongate tubular member having a proximal end, a distal end, and a lumen therebetween;
a bioresorbable body contained within the elongate tubular member, the bioresorbable body comprising polyglycolic acid; and
a radiopaque marker carried by the bioresorbable body.
32-37. (Canceled)
38. A method for marking a biopsy cavity comprising the steps of:
providing a bioresorbable body having a radiopaque marker carried by the bioresorbable body, said bioresorbable body comprising polyglycolic acid;
removing a biopsy specimen from the breast of a patient, thereby creating a biopsy site;
inserting the bioresorbable body into the biopsy site to mark the location of the biopsy site; and
testing the biopsy specimen.
39-46. (Canceled)
Description
  • [0001]
    This application is a continuation of U.S. application Ser. No. 10/839,112, filed May 4, 2004, which is a continuation of U.S. application Ser. No. 10/027,157, filed Dec. 20, 2001, now issued as U.S. Pat. No. 6,730,042, which is a continuation of U.S. application Ser. No. 09/900,801, filed Jul. 6, 2001, now issued as U.S. Pat. No. 6,699,205, which is a continuation of U.S. application Ser. No. 09/336,360, filed Jun. 18, 1999, now issued as U.S. Pat. No. 6,270,464, which application claims the benefit of the following Provisional patent applications: Biopsy Localization Device, Application No. 60/090,243, filed Jun. 22, 1998; Biopsy Localization and Hemostasis Device, Application No. 60/092,734, filed Jul. 14, 1998; Device and Method of Biopsy Localization and Hemostasis, Application No. 60/114,863, filed Jan. 6, 1999; and Device and Method of Biopsy Localization, Hemostasis & Cancer Therapy, Application No. 60/117,421, filed Jan. 27, 1999, all of which are herein expressly incorporated by reference in their entirety.
  • BACKGROUND OF THE INVENTION
  • [0002]
    In the U.S. alone approximately one million women will have breast biopsies because of irregular mammograms and palpable abnormalities. See FIG. 1 which diagrams the current treatment algorithm for non-palpable breast lesions. Biopsies can be done in a number of different ways for non-palpable lesions, including surgical excisional biopsies and stereotactic and ultrasound guided needle breast biopsies. In the case of image directed biopsy, the radiologist or other physician takes a small sample of the irregular tissue for laboratory analysis. If the biopsy proves to be malignant, additional surgery (typically a lumpectomy or a mastectomy) is required. The patient then returns to the radiologist a day or two later where the biopsy site (the site of the lesion) is relocated by method called needle localization, a preoperative localization in preparation for the surgery.
  • [0003]
    Locating the previously biopsied area after surgical excision type of biopsy is usually not a problem because of the deformity caused by the surgery. However, if the biopsy had been done with an image directed needle technique, as is common, help in relocating the biopsy site is usually needed. One procedure to permit the biopsy site to be relocated by the radiologist during preoperative localization is to leave some of the suspicious calcifications; this has its drawbacks.
  • [0004]
    Another way to help the radiologist relocate the biopsy site involves the use of a small metallic surgical clip, such as those made by Biopsys. The metallic clip can be deployed through the biopsy needle, and is left at the biopsy site at the time of the original biopsy. With the metallic clip as a guide, the radiologist typically inserts a barbed or hooked wire, such as the Hawkins, Kopans, Homer, Sadowski, and other needles, back into the patient's breast and positions the tip of the wire at the biopsy site using mammography to document the placement. The patient is then taken to the operating room with the needle apparatus sticking out of the patient's breast. While the clip provides a good indication of the biopsy site to the radiologist during preoperative localization, the clip remains permanently within the 80% of patients with benign diagnoses. Also, because the clip is necessarily attached to a single position at the periphery of the biopsy site, rather than the center of the biopsy site, its location may provide a misleading indication of the location of diseased tissue during any subsequent medical intervention. In addition, the soft nature of breast tissue permits the tip of the barbed or hooked needle to be relatively easily dislodged from the biopsy site. The clip is also relatively expensive.
  • [0005]
    Another localization method involves the use of laser light from the tip of a optical fiber connected to a laser. A pair of hooks at the tip of the optical fiber secures the tip at the biopsy site; the glow indicates the position of the tip through several centimeters of breast tissue. This procedure suffers from some of the same problems associated with the use of barbed or hooked wires. Another preoperative localization procedure injects medical-grade powdered carbon suspension from the lesion to the skin surface. This procedure also has certain problems, including the creation of discontinuities along the carbon trail.
  • SUMMARY OF THE INVENTION
  • [0006]
    The present invention is directed to a biopsy localization method and device which uses a locatable bioabsorbable element left at the biopsy site so that if testing of the biopsy sample indicates a need to do so, the biopsy site can be relocated by finding the bioabsorbable element. This eliminates the need to use of metallic clips during biopsies and often eliminates the need for a return to the radiologist for preoperative needle localization. In addition, the bioabsorbable element can be used as a therapeutic tool for treatment of the diseased lesion and for hemostasis.
  • [0007]
    A biopsy localization device made according to the invention includes a bioabsorbable element delivered in a pre-delivery state to a soft tissue biopsy site of a patient by an element delivery device. The bioabsorbable element may be palpably harder than the surrounding soft tissue at the biopsy site when in the post-delivery state.
  • [0008]
    One preferred material used as the bioabsorbable element is a dehydrated collagen plug. This type of plug may swell and is palpable for subsequent location by the surgeon. The collagen plug may not swell at all. In some situations, such as with small breasted women or where the biopsy site is close to the surface, a non-swellable bioabsorbable material, such as a round pellet of PGA, can be used instead of a swellable bioabsorbable material. The bioabsorbable material can also be made so that it is absorbed quickly to produce a local tissue inflammation; such a localized inflammation can be used to locate the biopsy site instead of location by palpation. Instead of leaving, for example, a collagen plug, a PGA pellet or a bioabsorbable suture material at the biopsy site for location by palpation or inflammation, a length of bioabsorbable suture material, a collagen filament, or other bioabsorbable material extending from the biopsy site out through the skin can be used. In this case the surgeon can follow the bioabsorbable suture material to the biopsy site in a manner similar to that used with Hawkins needles. In other cases, such as in the case of a deeply located lesion or large breast, the bioabsorbable material may need to be located by the radiologist, by for example, ultrasound or mammography. In any event the bioabsorbable material will typically be absorbed within about a month of placement. The invention thus eliminates the use of metal clips during biopsies and usually eliminates the need for return to the radiologist for preoperative localization.
  • [0009]
    While the primary use of the device is intended to localize the site of needle biopsies for possible future surgical excision, the device may also be useful in marking the site of surgical excisional biopsies. For example, during a wide surgical excision for cancer diagnosed by a recent surgical excisional biopsy, surgeons frequently have difficulty in determining the precise relationship of the previously excised tissue to the surgical wound. Therefore, more tissue is removed than might have been removed had the exact location of the previous lesion been more definite. With the present invention, a bioabsorbable element may be inserted into the biopsy site during a surgical excisional biopsy before the wound is closed to mark the site for potential wide excision should the biopsy reveal cancer. Alternatively, a bioabsorbable element may be placed at the biopsy site using a delivery device by partially or completely closing the wound and then depositing the bioabsorbable element through the delivery device and removing the delivery device through the closed incision. The presence of the palpable marker within the previous excisional biopsy site would allow the surgeon to more easily and confidently remove tissue around this site, and preserve more normal breast tissue.
  • [0010]
    Another use of the device is to primarily localize a non-palpable lesion prior to surgical excisional biopsy. Instead of using the needle/wire apparatus which has a tendency to migrate and become dislodged with traction, the palpable marker may be inserted into the suspicious area of the breast under mammographic or ultrasonic guidance immediately prior to the surgical excisional biopsy. This would provide a palpable locator for the surgeon as described above. In this instance, the marker would only need to be palpable, and not necessarily bioresorbable, since the intent would be to remove it in all cases.
  • [0011]
    In addition to permitting the biopsy site to be located by subsequent palpation or other means, the invention also can provide hemostasis and therapeutic benefits. The bioabsorbable element may comprise a therapeutic agent; the therapeutic agent may comprise at least a chosen one of a chemotherapeutic agent, a radiation agent and a gene therapy agent. Since the bloabsorbability can be varied from a day or two to a year or more, the material may be used to treat the diseased tissue and not just locate it. Some current therapies include radiation, chemotherapy, gene therapy as well as other technologies and therapies. Because the bioabsorbability can be easily varied, a medium can be place into the bioabsorbable element and be externally excited or triggered in those cases where the biopsy results are malignant. Further, the bioabsorbability concept can be used for future implantation of a therapeutic agent. For example, if the bioabsorbable element is a dehydrated collagen, this material could be used as a reservoir for, for example, delivery of materials that effect chemotherapy, brachytherapy, etc. Once the laboratory results are received and show the biopsy is malignant and therapy is required, by surgical excision or otherwise, the physician may inject, for example, a radiation pellet, a chemotherapeutic agent or a gene therapeutic agent into or adjacent to the bioabsorbable element for direct treatment of the diseased tissue.
  • [0012]
    The change in the bioabsorbable element can be via one of several ways, such as hydration or desiccation, change in temperature, electrical stimulation, magnetic stimulation, chemical or physical reaction with another material, additives, enzymatic reactions, ionization, electrical charges, absorption, as well as other means. The invention may employ one or more of these techniques or measures or others, to change the consistency, hardness and or size of the bioabsorbable element between its deployed and non-deployed states. The visual detectability of the bioabsorbable element may be aided by the use of a coloring agent, such as methylene blue or some other dye. The radiographic detectability of the element may be enhanced by a radiopaque marker. As well, ultrasonic detectability may be enhance by special treatment of the bioresorbable element.
  • [0013]
    The bioresorbable element may have margins which are roughened so as to prevent migration within the tissues. Filaments extending from the margins of the bioresorbable element may be utilized also to stabilize the position of the device within the cavity. The filaments may or may not be composed of the same material as the bioresorbable element.
  • [0014]
    The provision of hemostasis helps to lessen the bleeding and swelling within and about the biopsy site. This can be accomplished by physical or chemical means. That is, the device may swell so that it essential fills the biopsy cavity or the device may have a chemical reaction with blood or blood products to cause effective blood clotting, or both. Other methods for causing local hemostasis are also possible with the invention.
  • [0015]
    Other features and advantages of the invention will appear from the following description in which the preferred embodiments and methods have been set forth in detail in conjunction with the accompany drawings.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0016]
    FIG. 1 is a flow diagram of a conventional treatment algorithm for nonpalpable breast lesions;
  • [0017]
    FIG. 2 is a flow diagram of a treatment algorithm according to the present invention;
  • [0018]
    FIG. 3 is a simplified view illustrating a biopsy needle assembly obtaining a tissue sample of an abnormality at a target site;
  • [0019]
    FIG. 4 illustrates the main housing and sheath of the needle biopsy assembly left in place after the tissue sample has been removed leaving a biopsied open region at the target site;
  • [0020]
    FIG. 5 illustrates the barrel of the delivery device of FIG. 4 inserted into the main housing of the biopsy needle assembly and the plunger depressed injecting the bioabsorbable element into the biopsied open region, thus effectively filling the biopsied open region at the target site;
  • [0021]
    FIG. 6 illustrates the location of the bioabsorbable element of FIG. 5 with the surgeon using his or her fingers; and
  • [0022]
    FIG. 7 illustrates a bioabsorbable thread extending from the bioabsorbable element of FIG. 5 up through the patient's skin, the thread being delivered to the bioabsorbable element using the delivery device of FIGS. 4 and 5.
  • DESCRIPTION OF THE SPECIFIC EMBODIMENTS
  • [0023]
    FIG. 2 illustrates a treatment algorithm 2 according to the present invention. As a result of a routine mammography 4, a tumor or other abnormality may be detected as at 6. The typical response will often include additional magnification mammograms or a follow-up mammogram scheduled for some time in the future, such as six months. This is indicated at 8. If the tumor is not palpable, see 9, an image guided needle biopsy by a breast radiologist is typically conducted as at 10. Image guided needle biopsies can be done in a number of ways. Presently, stereotactic (x-ray) and ultrasound guided needle biopsies are commonly used, primarily because of their accuracy, speed and minimal trauma to the patient. Stereotactic needle biopsies typically use a stereotactic table, such as made by Fisher or Lorad, which provides mammography (x-ray) guidance to a biopsy needle assembly. Ultrasound guided biopsies can be conducted with any one of a number of commercially available instruments. An exemplary biopsy needle assembly 14, illustrated in FIG. 3, includes a biopsy needle 13 passing through a sheath 20 extending from a hollow main housing 22. The tip 12 of biopsy needle 13 of biopsy needle assembly 14 is automatically inserted to the abnormality 16 at the target site 18. Biopsy needle 13 has a laterally directed side opening 24 adjacent to tip 12 used to capture a tissue sample of abnormality 16. Once the tissue samples have been obtained, the removed tissue creates a biopsied open region 26 at target site 18. See FIG. 4. Following the removal of biopsy needle 13 from sheath 20 and main housing 22, the barrel 30 of a bioabsorbable element delivery device 32 is inserted through main housing 22 and into sheath 20. Barrel 30 contains a bioabsorbable element 34, see FIG. 5 Bioabsorbable element 34 is, in this preferred embodiment, a plug of dehydrated collagen, such as that sold by several companies such as Davol, Datascope, Integra Life Sciences, Collagen Matrix, Vascular Solutions, et al. Bioabsorbable element 34 may swell on contact with an aqueous liquid within biopsied open region 26 and substantially fills the biopsied open region as suggested in FIG. 5. In this preferred embodiment, bioabsorbable element 34 is transformed from its pre-delivery state within barrel 30 to its post-delivery state at region 26 and in the process swells and becomes somewhat softer in its post-delivery state than in its pre-delivery state. However, in its post-delivery state, bioabsorbable element 34 is palpably harder, preferably at least about 1.5 times harder, than the surrounding soft tissue, typically breast tissue 36. This permits bioabsorbable element 34 at the target site 18 to be relocated by palpation of the patient by the physician, see FIG. 6, to find the bioabsorbable element 6 and as discussed in more detail below.
  • [0024]
    A bioabsorbable element could be made of materials other than collagen and could be in a form other than a solid, relatively hard plug in its pre-delivery state. For example, bioabsorbable element 34 in its pre-delivery state within barrel 30 could be in a liquid or otherwise flowable form; after being deposited at open region 26 at target site 18, the bioabsorbable element could change to become palpably harder than the surrounding tissue 36 to permit subsequent relocation of target site 18 by palpation. In some situations, it may be desired that bioabsorbable element 34 not change its size or hardness between its pre-delivery state and its post-delivery state, such as being palpably harder than the surrounding tissue 36 in both states. In a preferred embodiment, transformation of bioabsorbable element 34 is by contact with an aqueous liquid.
  • [0025]
    However, transformation of the bioabsorbable element, which can be in terms of, for example, hardness, texture, shape, size, or a combination thereof, can be due to other factors, such as application of thermal energy, radiation, magnetic energy, etc.
  • [0026]
    Returning again to FIG. 2, it is seen that after insertion of bioabsorbable element 34, the biopsy sample is sent to pathology for evaluation at 36. If the pathology report, which is available a day or two after the biopsy, is benign, the patient is so informed and the bioabsorbable element simply is absorbed by the patient within, for example, a month as at 38. If the pathology report is positive, so that cancer is found, the biopsied open region 26 at the target site 18 is located by the surgeon by palpation as suggested by FIG. 6. After finding the target site by palpation, which eliminates the need for preoperative localization by the radiologist, appropriate medical treatment, such as excisional surgery, can be performed.
  • [0027]
    If the tumor is palpable, the surgeon may choose to make a direct incisional biopsy as at 48. According to the present invention, bioabsorbable delivery device 32 could be used to place bioabsorbable element 34 at the site of the incisional biopsy. After removal of delivery device 32, the incision would be closed, the biopsy sample would be sent to pathology and the patient would go home with the procedure preceding as discussed above, starting with item 36.
  • [0028]
    It may be preferred that bioabsorbable element 34 also act as a hemostatic agent to stop bleeding at site 18 by virtue of physical means, by filling or substantially filling open region 26, as well as chemical means through the chemical interaction, such as coagulation, with blood components. In addition, bioabsorbable element 34 could be covered by a non-hemostatic degradable outer layer so that hemostasis or other action is delayed until the outer layer has been eroded. In some situations, it may be necessary or at least desirable to shield the bioabsorbable element from the blood or other body fluids until after the bioabsorbable element is in place at target site 18. This could be accomplished by, for example, physically isolating the bioabsorbable element from body fluids by using a removable physical barrier during delivery of the bioabsorbable element. Alternatively, a bioabsorbable coating or layer, as described above, may be used. The bioabsorbable element may be changed from its pre-delivery state to its post-delivery state in a variety of manners including hydration, changing the temperature, electrical stimulation, magnetic stimulation, chemical reaction with a stimulating agent, physically interaction with an activating member (such as a knife blade which could be used to slice open a capsule containing the bioabsorbable element), by ionizing the bioabsorbable element, or by absorption or adsorption of a fluid by the bioabsorbable element.
  • [0029]
    The invention may also be used to medically treat the patient. That is, the bioabsorbable element-could include a therapeutic element which would be activated only if the pathology report indicated the need for the medical treatment. Various ways of activating an agent in a bioabsorbable element could be used, such as injecting a radiation-emitting element at the vicinity of the target site, externally irradiating the target site, providing a triggering substance to the target site, manual pressure, photodynamic therapy, sclerosing chemistry, vibrational therapy, ultrasound, and the like. Alternatively, the bioabsorbable element could be made so that it includes no such activating agent; rather, medical treatment could be provided by, for example, delivery of a chemotherapy agent, a radiation emitting element, thermal energy, electrical energy, vibrational energy, gene therapy, vector therapy, anti-angiogenesis therapy. To facilitate the delivery, the bioabsorbable element may contain a radiopaque marker or may have properties to aid in detecting it by ultrasound, in addition to being palpable.
  • [0030]
    An important use for the invention is in the treatment of breast cancer. In one embodiment, it is desirable that bioabsorbable element 34 in its post-delivery state have a hardness of at least about one and a half times that of breast tissue so that it is palpably harder than the surrounding tissue. Also, it is desired that bioabsorbable element 34, in one embodiment, swells from its pre-delivery state to its post-delivery state so to fill or at least substantially fills open region 26. To achieve this it is preferred that bioabsorbable element 34 swells about 50 to 1500%, and more preferably about 100 to 300%, from the pre-delivery state to the post delivery state, typically when placed in contact with an aqueous liquid. It is preferred that the bioabsorbable element has a longest dimension of at least about 0.5 cm in its post-delivery state to aid its location by palpation.
  • [0031]
    While the bioabsorbable element is preferably made of collagen in one embodiment, the bioabsorbable element can include, for example, one or more of the following materials; polyactic and polyglycolic acids, polyorthoesters, resorbable silicones and urethanes, lipids, polysaccharides, starches, ceramics, polyamino acids, proteins, hydrogels and other gels, gelatins, polymers, cellulose, elastin, and the like.
  • [0032]
    In some situations it may be desired to use a bioabsorbable filament 44 extending from bioabsorbable element 34 through the patient's skin 46 as shown in FIG. 7. This can be accomplished by delivering bioabsorbable filament 44 through sheath 20 as bioabsorbable element 34 is injected into region 26 at target site 18. In some situations it may not be possible or desirable to use bioabsorbable element 34; in those situations it may be useful to provide for only bioabsorbable filament 44 extending from target site 18 to above the patient's skin 46.
  • [0033]
    While it is presently preferred that bioabsorbable element delivery device 32 be guided through a portion of needle assembly 14, that is sheath 20 and main housing 22, in some situations it may be useful to cover sheath 20 with an outer sheath which would be left in place after the biopsy sample has been removed and the entire biopsy needle assembly 14 has been removed. The sheath left in place would then be used to guide barrel 30 of delivery device 32 to target site 18. Of course, delivery device 32 could take a number of different forms such as a syringe containing fluid or paste that is injected through a needle or through the housing 22 and sheath 20 or through an outer sheath. Alternatively, other delivery devices could be employed for delivery of bioresorbable element 34.
  • [0034]
    The invention has applicability toward the correction of a defect that is caused by breast tissue removal for biopsy or diseased tissue removal. Collagen is often placed in the body where it is eventually replaced by human autogenous tissue. Hence, the invention could be used for the repair of tissue that has been damaged due to tissue removal. The delivery device described heretofore could be used for installing a material (synthetic or mammalian) into the cavity for such a cosmetic or reconstructive repair. The material would typically be an effectively non-bioabsorable material, such as a silicon gel-filled capsule or bag.
  • [0035]
    Modification and variation can be made to the disclosed embodiments without departing from the subject of the invention as defined in the following claims.
  • [0036]
    Any and all patents, patent applications, and printed publications referred to above are incorporated by reference.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3818894 *3 Jan 197225 Jun 1974Ceskoslovenska Akademie VedLaryngeal implant
US4007732 *2 Sep 197515 Feb 1977Robert Carl KvavleMethod for location and removal of soft tissue in human biopsy operations
US4248214 *22 May 19793 Feb 1981Robert S. KishIlluminated urethral catheter
US4331654 *13 Jun 198025 May 1982Eli Lilly And CompanyMagnetically-localizable, biodegradable lipid microspheres
US4541438 *2 Jun 198317 Sep 1985The Johns Hopkins UniversityLocalization of cancerous tissue by monitoring infrared fluorescence emitted by intravenously injected porphyrin tumor-specific markers excited by long wavelength light
US4545367 *18 Nov 19838 Oct 1985Cordis CorporationDetachable balloon catheter and method of use
US4592356 *28 Sep 19843 Jun 1986Pedro GutierrezLocalizing device
US4647480 *1 Aug 19853 Mar 1987Amchem Products, Inc.Use of additive in aqueous cure of autodeposited coatings
US4655211 *8 Aug 19857 Apr 1987Unitika Ltd.Hemostatic agent
US4693237 *21 Jan 198615 Sep 1987Hoffman Richard BRadiopaque coded ring markers for use in identifying surgical grafts
US4763642 *7 Apr 198616 Aug 1988Horowitz Bruce SIntracavitational brachytherapy
US4774948 *24 Nov 19864 Oct 1988Markham Charles WMarking and retraction needle having retrievable stylet
US4799495 *20 Mar 198724 Jan 1989National Standard CompanyLocalization needle assembly
US4813422 *6 Mar 198721 Mar 1989Healthcare Technological Resources, Inc.Bowel control probe and method for controlling bowel incontinence
US4817622 *22 Jul 19864 Apr 1989Carl PennypackerInfrared imager for viewing subcutaneous location of vascular structures and method of use
US4838280 *26 May 198813 Jun 1989Haaga John RHemostatic sheath for a biopsy needle and method of use
US4847049 *20 Mar 198711 Jul 1989Vitaphore CorporationMethod of forming chelated collagen having bactericidal properties
US4852568 *28 Dec 19871 Aug 1989Kensey Nash CorporationMethod and apparatus for sealing an opening in tissue of a living being
US4909250 *14 Nov 198820 Mar 1990Smith Joseph RImplant system for animal identification
US4966583 *3 Feb 198930 Oct 1990Elie DebbasApparatus for locating a breast mass
US4986279 *1 Mar 198922 Jan 1991National-Standard CompanyLocalization needle assembly with reinforced needle assembly
US5014713 *5 Dec 198914 May 1991Tarris Enterprises, Inc.Method and apparatus for measuring thickness of fat using infrared light
US5018530 *15 Jun 198928 May 1991Research Corporation Technologies, Inc.Helical-tipped lesion localization needle device and method of using the same
US5080655 *26 Apr 199014 Jan 1992Haaga John RMedical biopsy needle
US5083570 *18 Jun 199028 Jan 1992Mosby Richard AVolumetric localization/biopsy/surgical device
US5158084 *22 Nov 198927 Oct 1992Board Of Regents, The University Of Texas SystemModified localization wire for excisional biopsy
US5195988 *4 Nov 199123 Mar 1993Haaga John RMedical needle with removable sheath
US5197482 *2 Apr 199130 Mar 1993Research Corporation Technologies, Inc.Helical-tipped lesion localization needle device and method of using the same
US5221269 *15 Oct 199022 Jun 1993Cook IncorporatedGuide for localizing a nonpalpable breast lesion
US5236410 *11 Mar 199117 Aug 1993Ferrotherm International, Inc.Tumor treatment method
US5281408 *19 Jan 199325 Jan 1994Unger Evan CLow density microspheres and their use as contrast agents for computed tomography
US5282781 *25 Oct 19901 Feb 1994Omnitron International Inc.Source wire for localized radiation treatment of tumors
US5325857 *9 Jul 19935 Jul 1994Hossein NabaiSkin biopsy device and method
US5334216 *10 Dec 19922 Aug 1994Howmedica Inc.Hemostatic plug
US5334381 *30 Jun 19932 Aug 1994Unger Evan CLiposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5342283 *13 Aug 199030 Aug 1994Good Roger REndocurietherapy
US5353804 *17 Mar 199311 Oct 1994Peb Biopsy CorporationMethod and device for percutaneous exisional breast biopsy
US5388588 *4 May 199314 Feb 1995Nabai; HosseinBiopsy wound closure device and method
US5394886 *20 Sep 19937 Mar 1995Nabai; HosseinSkin biopsy plug and method
US5409004 *6 Apr 199425 Apr 1995Cook IncorporatedLocalization device with radiopaque markings
US5411520 *3 Feb 19932 May 1995Kensey Nash CorporationHemostatic vessel puncture closure system utilizing a plug located within the puncture tract spaced from the vessel, and method of use
US5422730 *25 Mar 19946 Jun 1995Barlow; Clyde H.Automated optical detection of tissue perfusion by microspheres
US5423321 *2 Feb 199413 Jun 1995Fontenot; Mark G.Detection of anatomic passages using infrared emitting catheter
US5467780 *19 Dec 199421 Nov 1995Nabai; HosseinBiopsy wound closure device and method
US5479936 *19 Dec 19942 Jan 1996Nabai; HosseinBiopsy wound closure device and method
US5483972 *19 Dec 199416 Jan 1996Nabai; HosseinBiopsy wound closure device
US5487392 *15 Nov 199330 Jan 1996Haaga; John R.Biopxy system with hemostatic insert
US5494030 *12 Aug 199327 Feb 1996Trustees Of Dartmouth CollegeApparatus and methodology for determining oxygen in biological systems
US5517997 *15 Sep 199421 May 1996Gabriel Medical, Inc.Transillumination of body members for protection during body invasive procedures
US5526822 *24 Mar 199418 Jun 1996Biopsys Medical, Inc.Method and apparatus for automated biopsy and collection of soft tissue
US5549560 *13 May 199327 Aug 1996Wijdeven Gijsbertus G P Van DeApparatus and method for injecting a pharmaceutical preparation in solid form
US5556410 *27 Sep 199317 Sep 1996M3 Systems, Inc.Surgical needle with stress-relocation means
US5636255 *5 Mar 19963 Jun 1997Queen's University At KingstonMethod and apparatus for CT image registration
US5643246 *24 Feb 19951 Jul 1997Gel Sciences, Inc.Electromagnetically triggered, responsive gel based drug delivery device
US5646146 *25 May 19958 Jul 1997Novo Nordisk A/SHeterocyclic compounds and their preparation and use
US5647374 *30 Dec 199415 Jul 1997North American ScientificNeedle for imaging and sampling
US5660185 *13 Apr 199526 Aug 1997Neovision CorporationImage-guided biopsy apparatus with enhanced imaging and methods
US5676925 *7 Jun 199514 Oct 1997Nycomed Imaging AsContrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
US5688490 *7 Feb 199618 Nov 1997Bracco International B.V.Mucoadhesive compositions for increasing the ultrasonic image contrast of the digestive tract
US5795308 *26 Jul 199618 Aug 1998Russin; Lincoln D.Apparatus for coaxial breast biopsy
US5807276 *23 Jun 199715 Sep 1998Russin; Lincoln DavidBiopsy device and method
US5873904 *24 Feb 199723 Feb 1999Cook IncorporatedSilver implantable medical device
US5899935 *4 Aug 19974 May 1999Schneider (Usa) Inc.Balloon expandable braided stent with restraint
US5902310 *21 Feb 199711 May 1999Ethicon Endo-Surgery, Inc.Apparatus and method for marking tissue
US6053876 *9 Jun 199925 Apr 2000Fisher; JohnApparatus and method for marking non-palpable lesions
US6056700 *13 Oct 19982 May 2000Emx, Inc.Biopsy marker assembly and method of use
US6071301 *1 May 19986 Jun 2000Sub Q., Inc.Device and method for facilitating hemostasis of a biopsy tract
US6161034 *2 Feb 199912 Dec 2000Senorx, Inc.Methods and chemical preparations for time-limited marking of biopsy sites
US6183497 *17 Jun 19996 Feb 2001Sub-Q, Inc.Absorbable sponge with contrasting agent
US6214045 *9 Oct 199810 Apr 2001John D. Corbitt, Jr.Bioabsorbable breast implant
US6228055 *19 May 19978 May 2001Ethicon Endo-Surgery, Inc.Devices for marking and defining particular locations in body tissue
US6231834 *2 Dec 199715 May 2001Imarx Pharmaceutical Corp.Methods for ultrasound imaging involving the use of a contrast agent and multiple images and processing of same
US6248057 *27 Jul 199919 Jun 2001Innerdyne, Inc.Absorbable brachytherapy and chemotherapy delivery devices and methods
US6270464 *18 Jun 19997 Aug 2001Artemis Medical, Inc.Biopsy localization method and device
US6335028 *5 Mar 19991 Jan 2002Biosphere Medical, Inc.Implantable particles for urinary incontinence
US6352662 *23 Aug 19995 Mar 2002Callaway Golf CompanyIntegral molded grip and shaft
US6356782 *2 Apr 199912 Mar 2002Vivant Medical, Inc.Subcutaneous cavity marking device and method
US6427081 *5 Sep 200030 Jul 2002Senorx, Inc.Methods and chemical preparations for time-limited marking of biopsy sites
US6589502 *27 Nov 19958 Jul 2003International Brachytherapy S.A.Radioisotope dispersed in a matrix for brachytherapy
US20020026201 *18 Sep 200128 Feb 2002Foerster Seth A.Methods for defining and marking tissue
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US756519129 Sep 200521 Jul 2009Senorx, Inc.Tissue site markers for in vivo imaging
US765150517 Jun 200226 Jan 2010Senorx, Inc.Plugged tip delivery for marker placement
US7792569 *16 Nov 20047 Sep 2010Senorx, Inc.Cavity-filling biopsy site markers
US787713323 May 200325 Jan 2011Senorx, Inc.Marker or filler forming fluid
US797045418 Jun 200828 Jun 2011Senorx, Inc.Marker delivery device with releasable plug
US798373423 May 200319 Jul 2011Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US815786210 Dec 201017 Apr 2012Senorx, Inc.Tissue marking implant
US817779218 Nov 200915 May 2012Senorx, Inc.Plugged tip delivery tube for marker placement
US82191826 Aug 201010 Jul 2012Senorx, Inc.Cavity-filling biopsy site markers
US822442413 Jul 200917 Jul 2012Senorx, Inc.Tissue site markers for in vivo imaging
US831161022 Jan 200913 Nov 2012C. R. Bard, Inc.Biopsy tissue marker
US83610821 Mar 201129 Jan 2013Senorx, Inc.Marker delivery device with releasable plug
US840162217 Dec 200719 Mar 2013C. R. Bard, Inc.Biopsy marker with in situ-generated imaging properties
US843783428 Sep 20117 May 2013C. R. Bard, Inc.Breast marker
US844738614 Dec 201021 May 2013Senorx, Inc.Marker or filler forming fluid
US848602830 Sep 201116 Jul 2013Bard Peripheral Vascular, Inc.Tissue marking apparatus having drug-eluting tissue marker
US84986938 Apr 201130 Jul 2013Senorx, Inc.Intracorporeal marker and marker delivery device
US857993129 Sep 201112 Nov 2013Bard Peripheral Vascular, Inc.Apparatus for the percutaneous marking of a lesion
US86262698 Jun 20117 Jan 2014Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US862627013 Jun 20127 Jan 2014Senorx, Inc.Cavity-filling biopsy site markers
US86348993 Feb 200621 Jan 2014Bard Peripheral Vascular, Inc.Multi mode imaging marker
US863931516 May 201328 Jan 2014Senorx, Inc.Marker or filler forming fluid
US866873721 Mar 201211 Mar 2014Senorx, Inc.Tissue marking implant
US867081830 Dec 200811 Mar 2014C. R. Bard, Inc.Marker delivery device for tissue marker placement
US871874525 May 20106 May 2014Senorx, Inc.Tissue site markers for in vivo imaging
US878443327 Apr 201222 Jul 2014Senorx, Inc.Plugged tip delivery tube for marker placement
US888015419 Jul 20134 Nov 2014Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US89654866 Dec 201324 Feb 2015Senorx, Inc.Cavity filling biopsy site markers
US903976328 Jan 201426 May 2015Senorx, Inc.Tissue marking implant
US90429656 Mar 201326 May 2015C. R. Bard, Inc.Biopsy marker with in situ-generated imaging properties
US904416225 Jan 20132 Jun 2015Senorx, Inc.Marker delivery device with releasable plug
US914934121 Nov 20116 Oct 2015Senorx, IncDeployment of polysaccharide markers for treating a site within a patient
US923793720 Feb 201519 Jan 2016Senorx, Inc.Cavity-filling biopsy site markers
US932706121 Sep 20093 May 2016Senorx, Inc.Porous bioabsorbable implant
US948055418 May 20151 Nov 2016Senorx, Inc.Tissue marking implant
US957907712 Dec 200728 Feb 2017C.R. Bard, Inc.Multiple imaging mode tissue marker
US95791595 Nov 201328 Feb 2017Bard Peripheral Vascular, Inc.Apparatus for the percutaneous marking of a lesion
US964909314 Jan 201616 May 2017Senorx, Inc.Cavity-filling biopsy site markers
US20030233101 *17 Jun 200218 Dec 2003Senorx, Inc.Plugged tip delivery tube for marker placement
US20040236212 *23 May 200325 Nov 2004Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
US20040236213 *7 Jan 200425 Nov 2004Senorx, Inc.Marker delivery device with releasable plug
US20050119562 *27 Oct 20042 Jun 2005Senorx, Inc.Fibrous marker formed of synthetic polymer strands
US20050143656 *16 Nov 200430 Jun 2005Senorx, Inc.Cavity-filling biopsy site markers
US20060036165 *29 Sep 200516 Feb 2006Senorx, Inc.Tissue site markers for in vivo imaging
US20060155190 *2 Mar 200613 Jul 2006Senorx, Inc.Imageable biopsy site marker
US20080039819 *26 Jul 200714 Feb 2008Senorx, Inc.Marker formed of starch or other suitable polysaccharide
US20080058640 *30 Oct 20076 Mar 2008Senoxrx, Inc.Marker formed of starch or other suitable polysaccharide
US20080254298 *29 May 200816 Oct 2008Meadwestvaco CorporationMethod for treating a substrate
US20090030309 *21 Feb 200829 Jan 2009Senorx, Inc.Deployment of polysaccharide markers
US20090131825 *18 Dec 200821 May 2009Senorx, Inc.Imageable biopsy site marker
US20090287078 *24 Jun 200819 Nov 2009Senorx, Inc.Marker or filler forming fluid
US20100010342 *13 Jul 200914 Jan 2010Senorx, Inc.Tissue site markers for in vivo imaging
US20110237943 *8 Jun 201129 Sep 2011Senorx, Inc.Fibrous marker and intracorporeal delivery thereof
USD71544224 Sep 201314 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD71594224 Sep 201321 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD71645024 Sep 201328 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
USD71645124 Sep 201328 Oct 2014C. R. Bard, Inc.Tissue marker for intracorporeal site identification
Classifications
U.S. Classification128/899
International ClassificationA61B10/02, A61B19/00, A61B6/00, A61B17/34, A61B10/00
Cooperative ClassificationA61B2017/00004, A61B6/502, A61B17/3421, A61B10/02, A61B17/3468, A61B2090/3962, A61B2090/3987, A61B90/39, A61B2090/3908
European ClassificationA61B19/54
Legal Events
DateCodeEventDescription
13 Jul 2010ASAssignment
Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA
Free format text: SECURITY AGREEMENT;ASSIGNOR:ARTEMIS MEDICAL, INC.;REEL/FRAME:024672/0377
Effective date: 20100709